Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (16 OCT, 10.1038/s41591-023-02583-2, 2023 )

被引：0
|
作者：
Kirkwood, John M. [1 ]
Del Vecchio, Michele [2 ]
Weber, Jeffrey [3 ]
Hoeller, Christoph [4 ]
Grob, Jean-Jacques [5 ]
Mohr, Peter [6 ]
Loquai, Carmen [7 ]
Dutriaux, Caroline [8 ]
Chiarion-Sileni, Vanna [9 ]
Mackiewicz, Jacek [10 ]
Rutkowski, Piotr [11 ]
Arenberger, Petr [12 ,13 ]
Quereux, Gaelle [14 ]
Meniawy, Tarek M. [15 ,16 ]
Ascierto, Paolo A. [17 ]
Menzies, Alexander M. [18 ,19 ]
Durani, Piyush [20 ]
Lobo, Maurice [20 ]
Campigotto, Federico [20 ]
Gastman, Brian [21 ]
Long, Georgina V. [18 ,19 ]
机构：
[1] UPMC, Hillman Canc Ctr, Pittsburgh, PA 15232 USA
[2] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[3] NYU, Langone Med Ctr, New York, NY USA
[4] Med Univ Wien, Vienna, Austria
[5] Hop La Timone, Marseille, France
[6] Elbe Klinikum Buxtehude, Buxtehude, Germany
[7] Univ Med Ctr Mainz, Mainz, Germany
[8] Hop St Andre, Bordeaux, France
[9] IOV IRCCS, Ist Oncol Veneto, Padua, Italy
[10] Poznan Univ Med Sci, Inst Oncol, Poznan, Poland
[11] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[12] Charles Univ Prague, Fac Med 3, Prague, Czech Republic
[13] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic
[14] Nantes Univ Hosp, Nantes, France
[15] Univ Western Australia, Perth, WA, Australia
[16] Sir Charles Gairdner Hosp, Perth, WA, Australia
[17] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[18] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[19] Royal North Shore & Mater Hosp, Sydney, NSW, Australia
[20] Bristol Myers Squibb, Princeton, NJ USA
[21] Cleveland Clin, Cleveland, OH USA
来源：
NATURE MEDICINE | 2023年 / 30卷 / 2期
关键词：
D O I：
10.1038/s41591-023-02661-5
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：607 / 607
页数：1
相关论文
共 11 条
  • [1] Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
    Kirkwood, John
    Del Vecchio, Michele
    Weber, Jeffrey
    Hoeller, Christoph
    Grob, Jean-Jacques
    Mohr, Peter
    Loquai, Carmen
    Dutriaux, Caroline
    Chiarion-Sileni, Vanna
    Mackiewicz, Jacek
    Rutkowski, Piotr
    Arenberger, Petr
    Quereux, Gaelle
    Meniawy, Tarek M.
    Ascierto, Paolo A.
    Menzies, Alexander M.
    Durani, Piyush
    Lobo, Maurice
    Campigotto, Federico
    Gastman, Brian
    Long, Georgina V.
    NATURE MEDICINE, 2023, 29 (11) : 2835 - 2843
  • [2] Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
    John M. Kirkwood
    Michele Del Vecchio
    Jeffrey Weber
    Christoph Hoeller
    Jean-Jacques Grob
    Peter Mohr
    Carmen Loquai
    Caroline Dutriaux
    Vanna Chiarion-Sileni
    Jacek Mackiewicz
    Piotr Rutkowski
    Petr Arenberger
    Gaelle Quereux
    Tarek M. Meniawy
    Paolo A. Ascierto
    Alexander M. Menzies
    Piyush Durani
    Maurice Lobo
    Federico Campigotto
    Brian Gastman
    Georgina V. Long
    Nature Medicine, 2023, 29 : 2835 - 2843
  • [3] Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
    John M. Kirkwood
    Michele Del Vecchio
    Jeffrey Weber
    Christoph Hoeller
    Jean-Jacques Grob
    Peter Mohr
    Carmen Loquai
    Caroline Dutriaux
    Vanna Chiarion-Sileni
    Jacek Mackiewicz
    Piotr Rutkowski
    Petr Arenberger
    Gaelle Quereux
    Tarek M. Meniawy
    Paolo A. Ascierto
    Alexander M. Menzies
    Piyush Durani
    Maurice Lobo
    Federico Campigotto
    Brian Gastman
    Georgina V. Long
    Nature Medicine, 2024, 30 : 607 - 607
  • [4] Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (vol 29, pg 2835, 2023)
    Kirkwood, John M.
    Del Vecchio, Michele
    Weber, Jeffrey
    Hoeller, Christoph
    Grob, Jean-Jacques
    Mohr, Peter
    Loquai, Carmen
    Dutriaux, Caroline
    Chiarion-Sileni, Vanna
    Mackiewicz, Jacek
    Rutkowski, Piotr
    Arenberger, Petr
    Quereux, Gaelle
    Meniawy, Tarek M.
    Ascierto, Paolo A.
    Menzies, Alexander M.
    Durani, Piyush
    Lobo, Maurice
    Campigotto, Federico
    Gastman, Brian
    Long, Georgina V.
    NATURE MEDICINE, 2024, 30 (03) : 906 - 906
  • [5] Adjuvant Therapy With Nivolumab Versus Placebo in Patients With Resected Stage IIB/C Melanoma (Checkmate 76K)
    Gastman, Brian
    Long, Georgina V.
    Kirkwood, John M.
    Hoeller, Christoph
    Weber, Jeffrey
    Grob, Jean-Jacques
    Mohr, Peter
    Grabbe, Stephan
    Dutriaux, Caroline
    Chiarion-Sileni, Vanna
    Mackiewicz, Jacek
    Rutkowski, Piotr
    Arenberger, Petr
    Quereux, Gaelle
    Meniawy, Tarek
    Ascierto, Paolo A.
    van Akkooi, Alexander
    Durani, Piyush
    Campigotto, Federico
    Del Vecchio, Michele
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S35 - S36
  • [6] Adjuvant nivolumab v placebo in stage IIB/C melanoma: 3-year results from CheckMate 76K
    Long, G. V.
    Del Vecchio, M.
    Hoeller, C.
    Weber, J. S.
    Grob, J. J.
    Mohr, P.
    Grabbe, S.
    Dutriaux, C.
    Sileni, V. Chiarion
    Mackiewicz, J.
    Rutkowski, P.
    Arenberger, P.
    Quereux, G.
    Meniawy, T.
    Ascierto, P. A.
    Taube, J.
    Nassar, A.
    Wang, W.
    Kirkwood, J. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S713 - S714
  • [7] Adjuvant nivolumab (NIVO) v placebo (PBO) in stage IIB/C melanoma: Update from CheckMate 76K
    Kirkwood, J. M.
    Weber, J.
    Hoeller, C.
    Grob, J.
    Mohr, P.
    Grabbe, S.
    Dutriax, C.
    Chiarion-Sileni, V.
    Mackiewicz, J.
    Rutkowski, P.
    Arenberger, P.
    Meniawy, T.
    Dalle, S.
    Mandala, M.
    van Akkooi, A.
    Nassar, A.
    Campigotto, F.
    Long, G. V.
    Del Vecchio, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (08) : S48 - S48
  • [8] Adjuvant Nivolumab (NIVO) Versus Ipilimumab (IPI) in Resected Stage III/IV Melanoma: 3-Year Efficacy and Biomarker Results From the Phase 3 Checkmate 238 Trial
    Weber, J.
    Del Vecchio, M.
    Mandala, M.
    Gogas, H.
    Arance, A. M.
    Dalle, S.
    Cowey, C. L.
    Schenker, M.
    Grob, J.
    Chiarion-Sileni, V.
    Marquez-Rodas, I.
    Butler, M.
    Maio, M.
    Vetto, J.
    Tang, H.
    Saci, A.
    de Pril, V.
    Lobo, M.
    Larkin, J.
    Ascierto, P. A.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S144 - S144
  • [9] Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
    Weber, J. S.
    Del Vecchio, M.
    Mandala, M.
    Gogas, H.
    Arance, A. M.
    Dalle, S.
    Cowey, C. L.
    Schenker, M.
    Grob, J. J.
    Chiarion-Sileni, V.
    Marquez-Rodas, I.
    Butler, M. O.
    Maio, M.
    Middleton, M. R.
    Tang, T.
    Saci, A.
    De Pril, V.
    Lobo, M.
    Larkin, J. M. G.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2019, 30 : 533 - +
  • [10] Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
    Ascierto, Paolo A.
    Del Vecchio, Michele
    Mandala, Mario
    Gogas, Helen
    Arance, Ana M.
    Dalle, Stephane
    Cowey, C. Lance
    Schenker, Michael
    Grob, Jean-Jacques
    Chiarion-Sileni, Vanna
    Marquez-Rodas, Ivan
    Butler, Marcus O.
    Maio, Michele
    Middleton, Mark R.
    de la Cruz-Merino, Luis
    Arenberger, Petr
    Atkinson, Victoria
    Hill, Andrew
    Fecher, Leslie A.
    Millward, Michael
    Khushalani, Nikhil, I
    Queirolo, Paola
    Lobo, Maurice
    de Pril, Veerle
    Loffredo, John
    Larkin, James
    Weber, Jeffrey
    LANCET ONCOLOGY, 2020, 21 (11): : 1465 - 1477
12